Unexpected elevation of pentosidine formation in collagen incubated with glucose by low concentrations of the AGE-inhibitor aminoguanidine [2]

Diabetologia

Volumn 47, Issue 5, 2004, Pages 959-961

  Urios, P ^a,b   Grigorova Borsos, A M ^a,b   Sternberg, M ^a,b,c  

^a HÔTEL DIEU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL SAINT VINCENT DE PAUL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; BOVINE SERUM ALBUMIN; COLLAGEN; ERYTHROPOIETIN; GLUCOSE; LOW DENSITY LIPOPROTEIN; OXYGEN; PENTOSE; PENTOSIDINE; PYRIDOXAMINE; RIBOSE; TRACE METAL;

AIR; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DRUG EFFECT; ENDOTHELIUM CELL; ERYTHROCYTE; EXTRACELLULAR MATRIX; GLUCOSE BLOOD LEVEL; GLYCATION; HUMAN; IN VIVO STUDY; KIDNEY DISEASE; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; UREMIA;

ANIMALS; ARGININE; CATTLE; COLLAGEN; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; KINETICS; LYSINE;

EID: 2942628066     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-004-1399-2     Document Type: Letter

References (13)

1. Monnier V, Fogarty JF, Monnier CS, Sell DR (1999) Glycation, glycoxidation and other Maillard reaction products. In: Byung PY (ed) Methods in aging research. CRC Press, Washington DC, pp 657-681
2. Sell DR, Lapolla A, Odetti P, Fogarty J, Monnier VM (1992) Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 41:870-880
3. 1c as markers of diabetic complications. Diabetes 48:870-880
4. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232:1629-1632
5. Thornalley PJ (2003) Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 419:31-40
6. Woessner JF (1961) The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 93:440-447
7. Price DL, Rhett PM, Thorpe SR, Baynes JW (2001) Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 276:48967-48972
8. Urios P, Borsos A-M, Garaud J, Feing-Kwong-Chan S, Sternberg M (2002) At low concentration, aminoguanidine markedly increases pentosidine formation in collagen incubated with glucose, whereas decreasing it at high level. In: Horiuchi S et al. (eds) The Maillard Reaction in Food Chemistry and Medial Science: update for the postgenomic era. Exerpta Medica International Congress Series, Amsterdam, p 413
9. Culbertson SM, Vassilenko EI, Morrison LD, Ingold KU (2003) Paradoxical impact of antioxidants on post-Amadori glycoxidation: Counterintuitive increase in the yields of pentosidine and N-epsilon-carboxymethyllysine using a novel multifunctional pyridoxamine derivative. J Biol Chem 278:38384-38394
10. Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW (1995) Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 34:3702-3709
11. Bucala R, Makita Z, Vega G et al. (1994) Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91:9441-9445
12. Brown CD, Zhao ZH, Thomas LL, De Groof R, Friedman EA (2001) Effects of erythropoietin and aminoguanidine on red blood cell deformability in diabetic azotemic and uremic patients. Am J Kidney Dis 38:1414-1420
13. Freedman BI, Wuerth J-P, Cartwright K et al. (1999) Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy. Control Clin Trials 20:493-510